

Claims

1. Use of a composition in the manufacture of a medicament for stimulating the development of a healthy intestinal flora and/or decreasing the occurrence of intestinal pathogens in infants delivered via caesarean section within 3 months of birth, wherein the composition is not human milk and wherein the composition comprises:

(a) 0.5 to 75 g of non-digestible oligosaccharides per 100 g dry weight of the composition, wherein the non-digestible oligosaccharides comprise galacto-oligosaccharides having at least 50% of its saccharide units of the galacto-oligosaccharides as galactose units, and

(b) at least one *Bifidobacterium* selected from the group consisting of *B. Longum*, *B. Breve*, *B. infantis*, *B. catenulatum*, *B. pseudocatenulatum*, *B. adolescentis*, *B. animalis*, *B. gallicum*, *B. lactis* and *B. Bifidum*.

2. Use according to claim 1, wherein the composition further comprises at least fructo-oligosaccharides.

3. Use according to claim 2, wherein the fructo-oligosaccharides comprise inulins.

4. Use according to any one of claims 1 - 3, wherein the composition comprises galacto-oligosaccharides and/or fructo-oligosaccharides.

5. Use according to any one of claims 1 - 4, wherein the composition comprises a lipid component, a protein component and a carbohydrate component, wherein said lipid component provides 5 to 50% of the total calories, said protein component provides 5 to 50% of the total calories, said carbohydrate component provides 15 to 90% of the total calories.

6. Use according to any one of claims 1 - 5, wherein the composition comprises at least *B. Longum* and/or *B. Breve*.

7. Use according to any one of claims 1 - 6, wherein the composition comprises at least two *Bifidobacteria* selected from the group consisting of *B. Longum*, *B.*

Breve, B. infantis, B. catenulatum, B. pseudocatenulatum, B. adolescentis, B. animalis, B. gallicum, B. lactis and B. Bifidum.

8. Use according to any one of claims 1 - 7, wherein the composition comprises long chain polyunsaturated fatty acids and/or nucleotides.
- 5 9. Use according to any one of claims 1 - 8, wherein the composition is to be administered to the infant within one week after birth, preferably within 100 hours after birth.